Comparison of diagnostic accuracy of endometrial curettage and aspiration biopsy in patients with endometrial hyperplasia treated with progesterone

Comparing the diagnostic accuracy of Pipel with D&C and the histological results of these two methods in patients with endometrial hyperplasia treated with progesterone

A single-blind, phase 3, single-group clinical trial on 84 pregnant women. The sampling method will be available (non-probability) sampling method.

84 women referring to Kosar Qazvin Hospital with AUB who will undergo D&C and will be diagnosed with endometrial hyperplasia, all of whom will undergo a transvaginal ultrasound and endometrial thickness measurement, and no focal lesions will be seen in their ultrasound, will be included in the study. All patients will be fully informed about the aims and methods of the study and their voluntary informed consent will be taken to participate in the study. Patients will be treated with medroxyprogesterone tablets 20 mg daily for 15 days to 3 months (with each treatment regimen). After 4 weeks of completion of treatment, endometrial samples will be taken from each patient through 2 methods: Pipel followed by D&C. In this way, after general anesthesia, a sample of the papule will be taken first, and then dilation and curettage will be performed. The samples will only be sent to a specific pathologist in the form of endometrial samples number one and two (for lack of information) and their results will be compared.

Inclusion criteria: Women of reproductive age 18-47 years with AUB who underwent D&C and diagnosed with endometrial hyperplasia. Exclusion criteria: The patient's unwillingness to participate in the study; Presence of focal endometrial lesion

20 mg medroxyprogesterone pills are taken daily for 15 days to 3 months. After 4 weeks, the endometrial sample will be taken through 2 methods.

Endometrial hyperplasia

This study is one-sided blind. The samples are only sent to a specific pathologist, and in order for the pathologist not to know the type of sample, the samples are sent to pathology under the title endometrial sample 1 (for papillitis) and endometrial sample 2 (for dilatation and curettage) and their results are compared. will be

The collected information is in the form of a questionnaire and is statistically analyzed.

The start of the access period is one year after the results are published.

For obstetricians and researchers working in academic institutions

Evaluate the path and process of study and analyze it

For information, refer to Dr. Bahar Gholamnia. The communication channels are as follows: By sending an email to the address: bahar.gholamnia@ymail.com or referring and contacting Kosar Hospital at the address: Qazvin, Taleghani St. Phone: 028-33236374 Postal address: 34156-13176

After sending the e-mail, the requested information will be reviewed by the facilitator and the person responsible for the scientific responsibility of the study. At your discretion, the requested information will be sent within 10 days of receiving the email.